ImmunoPrecise Antibodies Ltd. (TQB.F)

1.0900 -0.0200 (-1.80%) As of 03:32PM CEST. Market open.

ImmunoPrecise Antibodies Ltd.

3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada
250-483-0308
https://www.ipatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 102

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jennifer Lynne Bath Ph.D.	CEO, President & Non-Independent Director	947.04k	N/A	N/A
Dr. Ilse Roodink	Chief Scientific Officer & Interim General Manager of IPA Europe, Oss	256.37k	N/A	N/A
Ms. Kristin Taylor CPA, M.B.A.	Chief Financial Officer	N/A	N/A	N/A
Mr. David E. Orton	Chief Operating Officer	N/A	N/A	N/A
Dr. Roland Romijn	Head of General Operations of the Utrecht site of IPA (Europe)	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Corporate governance

ImmunoPrecise Antibodies Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.